American Marconi Wireless News - Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist

NYSE - LSE

RYCEF	8.01%	17.86	$
RBGPF	0%	75.17	$
CMSD	1.61%	20.48	$
CMSC	2%	20.46	$
BCE	-0.6%	21.49	$
BCC	3.21%	72.57	$
NGG	1.32%	84.26	$
GSK	2.35%	51.54	$
RIO	3.08%	86.39	$
BTI	-1.33%	60.09	$
VOD	0.7%	15.69	$
RELX	-0.37%	40.02	$
BP	0.13%	44.59	$
JRI	2.51%	11.93	$
AZN	1.56%	189.39	$

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

ECONOMY 27.01.2026

JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.

Text size:

Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about Jupiter Neurosciences at www.jupiterneurosciences.com.

Event Details:

Conference: 3rd Annual DealFlow Discovery Conference
Venue: The Borgata Hotel, Casino & Spa
Location: Atlantic City, NJ
Date: January 28-29, 2026

Investors interested in scheduling a meeting with the Jupiter Neurosciences management team should request an investor pass to attend the conference (no cost to attend).

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Media Contact:

Christer Rosén
Chairman and CEO
Jupiter Neurosciences, Inc.
[email protected]

SOURCE: DealFlow Events

View the original press release on ACCESS Newswire

L.Mason--AMWN

American Marconi Wireless News - Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Featured

Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems

RBI Data Reveals Divergence in Credit Card Spending and Debit Card Cash Withdrawals

First-time boat buyers advised to assess full ownership costs

US Treasury order targets bank transfers linked to crypto exchange MEXC